BBC reports;
“GlaxoSmithKline believes it has developed a vaccine for the H5N1 deadly strain of bird flu that may be capable of being mass produced by 2007.The vaccine has proved effective at two doses of 3.8 micrograms during clinical trials in Belgium, BBC business editor Robert Peston has learned.
It is the size of the dose that is highly significant, Glaxo explained.”
Related;
Bird flu: risks, laws and rights
Responding to the Threat of a Pandemic Influenza- Frederick G. Hayden, Prof. of Clinical Virology in International Medicine at U. of Va. School of Medicine, considers the effectiveness and potential for resistance offered by antivirals.
The popular Avian Flu blog is now dormant.
